Eluminex Biosciences

Executive Summary

Eluminex Biosciences is a private, San Diego-based biopharmaceutical company focused on developing novel biologic therapies for serious ophthalmic and inflammatory diseases. Founded in 2020, the company has raised $40 million to advance its pipeline, which targets validated pathways using engineered proteins to improve efficacy and durability. Its lead program is aimed at geographic atrophy (GA), a leading cause of blindness, and is currently in Phase 2 clinical development. By leveraging a deep understanding of disease biology, Eluminex aims to address significant unmet need in the ophthalmology space, where treatment options for GA remain limited. The company's approach may offer advantages over existing therapies through enhanced target binding and prolonged intraocular retention, potentially translating to better visual outcomes for patients. Looking ahead, Eluminex is positioned to reach several key milestones. The company is likely to report initial Phase 2 data for its GA candidate within the next 12 months, which will be a critical value inflection point. Additionally, Eluminex may seek to raise further capital to support a pivotal Phase 3 program and expand its pipeline into additional inflammatory indications. A partnership with a larger pharmaceutical company for ex-US rights or co-development is also a possibility, given the commercial potential of a GA therapy. With a seasoned management team and a focused strategy, Eluminex represents a promising but early-stage investment opportunity in the ophthalmology space.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 data readout for lead geographic atrophy candidate40% success
• H2 2026Series B financing round to fund Phase 2/3 development70% success
• 2026Partnership for ex-US licensing or co-development rights50% success